Novel biological therapies for inflammatory bowel disease
- 26 Downloads
The success of biological therapy is best advocated by infliximab (IFX), which has dramatically improved medical therapy for Crohn’s disease and now has been shown to be effective in the treatment of ulcerative colitis. Other anti-tumor necrosis factor (TNF) compounds have been tested in the treatment of Crohn’s disease and will soon appear in the therapeutic armament. However, neutralization of TNF does not seem to be the most important mechanism of action of these therapies. Apoptosis of activated T cells was demonstrated after IFX treatment, and this may be the key to its success. Thus, other therapies that induce apoptosis in activated T cells, such as visilizumab, have a great chance to be of benefit. Biological therapies applied in inflammatory bowel disease appear to be safe, although therapy-related adverse events clearly have been recognized.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 3.Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 2006, 6:9–20. This review focuses on the role of TLR and NOD proteins in the pathogenesis of disease, discussing the role of the disease-associated mutations in CARD15/NOD2 in a functional context.PubMedCrossRefGoogle Scholar
- 11.Braat H, Steidler L, Neirynck S, et al.: Turbo-Probiotics as a tool for cell based (mucosal) delivery of interleukin-10 [abstract]. Gastroenterology 2005, 128(Suppl 4):A27.Google Scholar
- 12.Braat H, Rottiers P, Huyghebaert N, et al.: Interleukin-10 producing Lactococcus lactis for the treatment of Crohn’s disease [abstract]. Gastroenterology 2005, 128(Suppl 4):A685.Google Scholar
- 31.Rutgeerts P, Sandborn WJ, Feagan BG, et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462–2476. Here, the results of the ACT 1 and 2 trials are described. These trials provide strong arguments for registration of IFX for the treatment of UC.PubMedCrossRefGoogle Scholar
- 38.Hanauer SB, Sandborn WJ, Rutgeerts P, et al.: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323–333. The results of the phase III trial that paves the way for the second effective anti-TNF compound that can be used for treatment of Crohn’s disease.PubMedCrossRefGoogle Scholar
- 52.Hommes DW, Plevy SE, Salzberg B, et al.: Epstein Barr Virus (EBV) replication in severe active, steroid resistant ulcerative colitis (UC) patients treated with visilizumab, an anti-CD3 antibody [abstract]. Gastroenterology 2005, 128:A494.Google Scholar